Harmony’s cannabidiol drug flops in pivotal Fragile X Syndrome trial
Harmony Biosciences’ transdermal cannabidiol ZYN002 suffered a setback as a Phase III trial failed to meet the primary endpoint in…
News
MSD pays up to nearly $600m for Evaxion’s mystery vaccine candidate
BMS expands DTC offering with Sotyktu addition
Basilea in line for $159m of US federal funding for UTI antibiotic pill
UniQure stock surges 247% after mid-stage Huntington’s win
Moderna opens UK vaccine manufacturing facility
Sanofi announces $625m to venture capital arm
Roche bids to broaden MS pipeline and strengthen Ocrevus influence
